Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2024; 15(3): 455-462
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.455
Evaluation of hybrid closed-loop insulin delivery system in type 1 diabetes in real-world clinical practice: One-year observational study
Ahmed Eldib, Shilton Dhaver, Karim Kibaa, Astrid Atakov-Castillo, Tareq Salah, Marwa Al-Badri, Abdelrahman Khater, Ryan McCarragher, Omnia Elenani, Elena Toschi, Osama Hamdy
Ahmed Eldib, Shilton Dhaver, Karim Kibaa, Astrid Atakov-Castillo, Tareq Salah, Marwa Al-Badri, Abdelrahman Khater, Ryan McCarragher, Omnia Elenani, Elena Toschi, Osama Hamdy, Department of Clinical, Behavioral & Outcomes Research, Joslin Diabetes Center, Boston, MA 02215, United States
Ahmed Eldib, Karim Kibaa, Tareq Salah, Marwa Al-Badri, Abdelrahman Khater, Elena Toschi, Osama Hamdy, Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
Author contributions: Eldib A, Dhaver S, Kibaa K and Hamdy O have full access to all study data and take responsibility for data integrity and accuracy of data analysis; Eldib A designed the study, collected data, conducted the statistical analysis, and prepared the manuscript; Dhaver S and Kibaa K collected data, conducted the statistical analysis, and prepared the manuscript; Atakov-Castillo A collected data and reviewed the manuscript; Al-Badri M, Salah T, Khater A, McCarragher R, Elenani O prepared, reviewed, and edited the manuscript; Toschi E and Hamdy O designed and supervised the study, reviewed, and edited the manuscript; all authors approved the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Committee on Human Studies at the Joslin Diabetes Center (Approval No. 2017-14).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Eldib A, Dhaver S, Kibaa K, Atakov-Castillo A, Salah T, Al-Badri M, Khater A, McCarragher R, Elenani O, Toschi E: Nothing to disclose. Hamdy O: Consultant to Abbott Nutrition, Sanofi Aventis; his employer Joslin Diabetes Center receives research grants from Novo-Nordisk, Eli-Lilly, Gilead Sciences, and National Dairy Council; on SAB of Twin Health; and is a shareholder of Healthimation Inc.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at tareq.salah@joslin.harvard.edu. No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tareq Salah, MD, Research Fellow, Department of Clinical, Behavioral & Outcomes Research, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, United States. tareq.salah@joslin.harvard.edu
Received: October 26, 2023
Peer-review started: October 26, 2023
First decision: November 30, 2023
Revised: December 8, 2023
Accepted: January 15, 2024
Article in press: January 15, 2024
Published online: March 15, 2024
Core Tip

Core Tip: There has been a growing emphasis on patient-centered healthcare and there are limited data on the impact of hybrid-closed-loop systems on quality-of-life measures. In this study, we aimed to evaluate the glycemic control and quality of life measures in patients with type 1 diabetes in a real-world clinical practice who used hybrid closed loop systems showed improvements in A1C, percent time in optimal glucose range, emotional burden and distress due to diabetes, physical functioning, and fear of hypoglycemia.